March 25, 2020 07:10 AM EDTUpdated 08:39 AM
Deals
Discovery

Join­ing No­var­tis in siR­NA space, As­traZeneca hands Si­lence $80M up­front for dis­cov­ery deal

Amber Tong

Mene Pan­ga­los is dou­bling down on RNA-based tech­nolo­gies for his side of the As­traZeneca R&D ma­chine.

Just two months af­ter bring­ing a small ac­ti­vat­ing RNA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

A service from the Financial Times